$RLFTF (related) $NRXP Statement from NRx CEO and
Post# of 653
The NRx team has just approved the final text of our application for Emergency Use Authorization of ZYESAMI™ to treat Critical Covid-19 in patients suffering respiratory failure. Together with the COVID-AIV trial investigators, we will be working through the Memorial Day weekend to ensure we file by Monday. We thank the hundreds of physicians, nurses, respiratory therapists, and other caregivers, together with the patients and their families who made this trial possible. At the same time, this Memorial Day, we mourn more than 600,000 Americans who have succumbed to COVID-19, more lives lost than in all the wars fought in the history of the Republic.